In turn, Cu(II)-complexes were evaluated for their anticancer properties against A549 cells, as well as NCI-H460 non-small cell lung carcinoma cells and EGFR-mutant NCI-H1975 non-small cell lung carcinoma cells. This evidence concerns the gene EGFR and non-small cell lung carcinoma.